top of page

About Us

02_A4-Studio-Mockups-Pack_Vol-01 copy.jpg

Mission Statement

At Choice PharmD, our mission is to empower healthcare providers with expert therapeutic guidance for interpreting molecular diagnostic tests. We are dedicated to advancing antimicrobial stewardship, promoting effective therapies, and improving patient outcomes by bridging molecular diagnostics with clinical expertise.

See How Treatment Guidance Works

Key Benefits of Choice PharmD

We aim to complete reports efficiently, providing treatment considerations to providers and therefore patient care in a timely manner. LIS integrations streamline workflow and allow for quick turnaround times (TAT) for results.

Efficiency

Each of our reports are reviewed by a trained pharmacist, which details medications that provide antimicrobial coverage for specific detected pathogens, making samples with multiple detected pathogens and resistance genes simpler to navigate and determine treatment for providers.

Therapeutic Guidance

Choice PharmD infographic showing key report benefits: stewardship, evidence-based guidance, therapeutic recommendations, and efficiency.

Our treatment considerations for medication selection, dosages, and durations are based on clinical practice guidelines (i.e. IDSA, CDC, etc.) as well as primary literature.

Evidence-based

Antimicrobial resistance is a growing concern. Therefore, judicious selection of antimicrobials is crucial for patient-centered care and optimizing outcomes. Our pharmacists specialize in clinical interpretation of resistance gene data, utilizing most recent published literature to help guide choice of antimicrobials.

Stewardship

Antimicrobial Stewardship

Antimicrobial resistance occurs when bacteria and fungi become resistant to the drugs designed to eliminate them, posing a critical global health threat. Therefore, improving antibiotic use through antimicrobial stewardship is essential for patient safety and combating antimicrobial resistance. 

Infographic on antimicrobial stewardship showing three key points: resistance causing 2.8 million infections and 35,000 deaths annually in the U.S., treatment costs exceeding $4.6 billion, and prevention efforts reducing deaths from antimicrobial resistance.

Resistance

Each year, over 2.8 million infections in the United States are linked to antimicrobial resistance, leading to more than 35,000 deaths annually.

Cost

Treatments related to antimicrobial resistance threats have resulted in over $4.6 billion in annual healthcare costs.

Prevention

Efforts for prevention, infection control, and improving appropriate antimicrobial use have shown to reduce deaths due to antimicrobial resistance.

How It Works

We integrate with your Laboratory Information System (LIS) to ensure fast, seamless, and accurate data transmission, enabling the efficient completion of PharmD reporting.

How Choice PharmD works infographic showing five steps: 1) Collection of patient sample, 2) Sample processed with PCR for pathogens and resistance genes, 3) Pharmacist review with treatment considerations, 4) Report transmission via LIS, 5) Provider uses report to guide treatment.

Collection

Sample Processed

Sample specimen is collected from presumed source of infection and shipped to appropriate lab.

Lab runs sample via PCR technology for detection of pathogens and resistance genes. Results are transmitted to Choice PharmD via an HL7 interface.

Pharmacist Review

Detected pathogens and resistance genes are carefully evaluated by a trained pharmacist to provide a report with evidence-based treatment considerations.

Treatment

Report Transmission

Completed PharmD reports are sent back to the LIS via SFTP and are merged with laboratory report.

Provider reviews Choice PharmD report along with lab results and selects drug therapy most appropriate for the patient.

bottom of page